Table 3. Pre-clinical studies regarding the effects on tumor microenvironment of BRAF-inhibitors.

Class of Drugs	Effect on microenvironment	Type of cancer	Model	ref
BRAFi, MEKi	Increase of Melanocyte Differentiation Agents	Melanoma	Bioptic samples of treated patients	Boni et al.
BRAFi, MEKi	Reduction of intratumoral Tregs	Melanoma	Braf/Pten mouse model of inducible, autochthonous melanoma on a pure C57BL/6 background	Steinberg et al. Ho et al.
BRAFi, MEKi	Reduction of MDSCs	Melanoma	Braf/Pten mouse model of inducible, autochthonous melanoma on a pure C57BL/6 background	Steinberg et al.
BRAFi, MEKi	Increased dendritic cells activation	Melanoma	co-cultured monocyte-derived human Dendritic cells with melanoma BRAF mutated cell lines	Ott et al. Hayek et al.
BRAFi	Increased intratumoral CD8+ T cells	Thyroid	immunocompetent orthotopic mouse model of V600E BRAF mutated Anaplastic thyroid cancer	Gunda et al, Vanen Borre et al.
		Melanoma	Braf(V600E)-driven mouse melanoma (SM1 and SM1WT1) and melanoma-prone mice	Knight et al.
BRAFi	Increased intratumoral B cells	Thyroid	immunocompetent orthotopic mouse model of V600E BRAF mutated Anaplastic throid cancer	Gunda et al, Vanen Borre et al.
BRAFi	Increased intratumoral Macrophages	Thyroid	immunocompetent orthotopic mouse model of V600E BRAF mutated Anaplastic throid cancer	Gunda et al, Vanen Borre et al.
BRAFi	Preserved normal cell viability	Thyroid	Normal thyrocytes (PC Cl 3)	Salerno et al.
BRAFi	Increased induction of MHC Class I and Class II molecules by IFN	Melanoma	Melanoma cell lines	Sapkota, et al.
BRAFi	CCL2 lowering	Melanoma	Braf(V600E)-driven mouse melanoma (SM1 and SM1WT1) and melanoma-prone mice	Knight et al.
BRAFi	CXCL8 lowering	Thyroid	NHT, 8505C, 8305C, BCPAP cell lines	Coperchini et al.